| Literature DB >> 35778672 |
Zhiqiang Zhang1,2, Zhangtian Xia1,2, Ge Luo1,2, Ming Yao3,4.
Abstract
INTRODUCTION: Postherpetic neuralgia (PHN) is a painful condition that persists for 1 month or more after herpes zoster rash has healed. Radiofrequency thermocoagulation (RF-TC) provides analgesia by destroying the dorsal root ganglion and blocking the pain upload pathway; nonetheless, the concomitant neurological-related side effects and recurrence remain a concern.Entities:
Keywords: Efficacy; Postherpetic neuralgia; Predictive model; Radiofrequency thermocoagulation; Recurrence factors; Safety
Year: 2022 PMID: 35778672 PMCID: PMC9314488 DOI: 10.1007/s40122-022-00412-x
Source DB: PubMed Journal: Pain Ther
Fig. 1Flowchart depicting the detailed process of patient enrollment
Fig. 2The radiofrequency puncture needle guided by CT is punctured to the rear of 1/3 on the intervertebral foramen (A); the puncture needle located in the intervertebral foramen under the three-dimensional reconstruction of CT (B)
Baseline characteristics (preoperative) of the numerical variables [mean ± SD or n (%) or median (IQR)]
| Variable | Negative ( | Positive ( |
|---|---|---|
| Age, years | 70.88 ± 9.17 | 71.92 ± 8.64 |
| BMI, kg/m2 | 23.16 ± 2.87 | 22.84 ± 2.52 |
| Course of disease, months | 3 (2–8) | 8 (3–36) |
| NRSs | 6 (5–6) | 6 (6–7) |
| Gender | ||
| Female | 63 (42.3) | 39 (49.4) |
| Male | 86 (57.7) | 40 (50.6) |
| Lesion side | ||
| Left | 69 (46.3) | 34 (43.0) |
| Right | 80 (53.7) | 45 (57.0) |
| Type of RF electrode | ||
| Monopole | 125 (83.9) | 78 (98.7) |
| Bipolar | 24 (16.1) | 1 (1.3) |
| Lesion segment | ||
| Chest and back | 104 (69.8) | 59 (74.7) |
| Waist and abdomen | 45 (30.2) | 20 (25.3) |
| Complications | ||
| Yes | 88 (59.1) | 60 (75.9) |
| No | 61 (40.9) | 19 (24.1) |
| Treatment history | ||
| Medication | 115 (77.2) | 69 (87.3) |
| Neuromodulation | 34 (22.8) | 10 (12.7) |
BMI Body mass index, NRSs numerical rating scale scores
The NRS score of the patient at the preoperative and postoperative in each time period (mean ± SD)
| Time | Preoperative | Postoperative | ||
|---|---|---|---|---|
| T1 | 42 | 5.90 ± 0.69 | 2.86 ± 2.08 | < 0.001 |
| T2 | 41 | 6.15 ± 0.79 | 3.49 ± 2.55 | < 0.001 |
| T3 | 39 | 5.85 ± 0.67 | 3.36 ± 2.42 | < 0.001 |
| T4 | 29 | 5.69 ± 0.71 | 3.28 ± 1.93 | < 0.001 |
| T5 | 21 | 5.95 ± 0.67 | 3.67 ± 2.31 | < 0.001 |
| T6 | 23 | 5.91 ± 0.67 | 3.30 ± 2.06 | < 0.001 |
| T7 | 10 | 6.00 ± 0.94 | 3.50 ± 2.95 | 0.008 |
| T8 | 11 | 6.00 ± 0.89 | 4.18 ± 2.44 | 0.008 |
| T9 | 8 | 5.88 ± 0.64 | 3.75 ± 2.96 | 0.049 |
| T10 | 4 | 6.00 ± 0.82 | 4.25 ± 2.63 | 0.188 |
T1 within 1 year after surgery, T2 between 1 and 2 years after surgery, T3 between 2 and 3 years after surgery, T4 between 3 and 4 years after surgery, T5 between 4 and 5 years after surgery, T6 between 5 and 6 years after surgery, T7 between 6 and 7 years after surgery, T8 between 7 and 8 years after surgery, T9 between 8 and 9 years after surgery, T10 between 9 and 10 years after surgery
Cumulative effictive rate, cumulative relapse rate, and median time to relapse after radiofrequency thermocoagulation
| Time | Cumulative effective rate (%) | Cumulative relapse rate (%) | Median time to relapse (months) |
|---|---|---|---|
| Within 1 year | 75.6 | 22.2 | 5 |
| Within 2 years | 63.3 | 32.6 | 13 |
| Within 3 years | 55.8 | 36.6 | 19 |
| Within 4 years | 44.6 | 42.0 | 28 |
| Within 5 years | 42.1 | 44.6 | 29 |
| Within 6 years | 37.6 | 47.9 | 33 |
| Within 7 years | 37.6 | 47.9 | 36 |
| Within 8 years | 37.6 | 47.9 | 37 |
| Within 9 years | 37.6 | 47.9 | 38 |
| Within 10 years | 37.6 | 47.9 | 38 |
Adverse events regarding surgery in all patients at each time point [n (%)]
| Adverse events | t0 | t1 | t2 | t3 | t4 | t5 |
|---|---|---|---|---|---|---|
| Total number | 228 | 228 | 228 | 228 | 186 | 146 |
| Intraoperative | ||||||
| The pain intensified | 164 (71.9) | |||||
| Bleeding | 7 (3.1) | |||||
| Nerve injury | 0 | |||||
| Postoperative | ||||||
| Abdominal muscle weakness | 42 (18.4) | 15 (6.6) | 0 | 0 | 0 | |
| Numbness | 203 (89.0) | 190 (83.3) | 111 (54.1) | 44 (23.7) | 15 (10.3) | |
t0 intraoperative, t1 lasting 1 day after surgery, t2 lasting 1 month after surgery, t3 lasting 6 months after surgery, t4 lasting 1 year after surgery, t5 lasting 2 years after surgery
Fig. 3Kaplan–Meier survival plot. For patients with disease course of 1–3 months versus with more than 3 months (A); for patients with monopolar versus with bipolar needles (B); for patients with complications versus with no complications (C); for patients with moderate versus with severe pain (D)
Factors associated with relapse after radiofrequency thermocoagulation for patients with postherpetic neuralgia
| Factors | Unadjusted analysis | Adjusted analysis | ||
|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | |||
| Gender | ||||
| Female | 0.724 (0.465–1.126) | 0.151 | 0.741 (0.466–1.176) | 0.203 |
| Male | ||||
| Age, years | ||||
| < 65 | 1.321 (0.753–2.318) | 0.332 | 1.278 (0.712–2.294) | 0.411 |
| ≥ 65 | ||||
| BMI, kg/m2 | ||||
| < 18.5 | Ref | Ref | ||
| 18.5–23.9 | 1.717 (0.517–5.702) | 0.378 | 1.860 (0.526–6.582) | 0.336 |
| ≥ 24 | 1.344 (0.378–0.226) | 0.226 | 1.046 (0.628–1.741) | 0.863 |
| Lesion segment | ||||
| Chest and back | 0.826 (0.497–1.372) | 0.461 | 1.131 (0.658–1.946) | 0.655 |
| Waist and abdomen | ||||
| Lesion side | ||||
| Left | 1.137 (0.727–1.778) | 0.574 | 1.139 (0.717–1.810) | 0.580 |
| Right | ||||
| Course of disease, months | ||||
| 1–3 | 2.389 (1.484–3.845) | < 0.001 | 2.086 (1.277–3.409) | 0.003 |
| > 3 | ||||
| Type of RF electrode | ||||
| Monopole | 0.200 (0.063–0.633) | 0.006 | 0.258 (0.080–0.831) | 0.023 |
| Bipolar | ||||
| Complications | ||||
| No | 2.010 (1.198–3.372) | 0.008 | 1.740 (1.015–2.983) | 0.044 |
| Yes | ||||
| Treatment history | ||||
| Medication | 0.710 (0.365–1.382) | 0.313 | 0.836 (0.422–1.658) | 0.609 |
| Neuromodulation | ||||
| Pain grade | ||||
| Moderate | 3.188 (2.013–5.050) | < 0.001 | 2.724 (1.654–4.485) | < 0.001 |
| Severe | ||||
BMI Body mass index
Fig. 4Receiver operating characteristic (ROC) curve of a 10-year overall recurrence prediction model in patients with postherpetic neuralgia after radiofrequency thermocoagulation
Fig. 5An established nomogram to predict survival based on a Cox model. The total score obtained by the addition of every risk factor in the vertical line corresponds to the predicted recurrence rate
Fig. 6Calibration curves of the nomogram for 1-year (A), 3-year (B), 5-year (C), and 8-year (D) relapse-free. Horizontal coordinate the predicted probability, vertical coordinate the actual probability, red line the goodness-of-fit, that is the actual value corresponding to the predicted value, blue line the 95% confidence interval of the relapse-free rate
| Postherpetic neuralgia (PHN) is the most common and severe complication of herpes zoster. The existing treatments are difficult to cure. |
| Radiofrequency thermocoagulation (RF-TC) provides analgesia by destroying the dorsal root ganglion and blocking the pain upload pathway; nonetheless, the concomitant neurological-related side effects and recurrence remain a concern. |
| With long-term follow-up, we observed that mean postprocedural NRS scores were lower than those at the preprocedural stage. No other complications were found except for numbness and abdominal bulging. Cox regression analysis demonstrated that disease course, complications, pain grade, and type of RF electrode were associated with a significantly higher risk of relapse. |
| In our opinion, CT-guided RF-TC of the dorsal root ganglion for PHN is a relatively safe and effective surgical option. If patients are willing to accept pain relief at the cost of numbness, RF-TC of the dorsal root ganglion should be considered. |